Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1997 Jul;35(7):1734-9.
doi: 10.1128/jcm.35.7.1734-1739.1997.

Serological determination of hepatitis C virus genotype: comparison with a standardized genotyping assay

J M Pawlotsky  1 , L Prescott, P Simmonds, C Pellet, P Laurent-Puig, C Labonne, F Darthuy, J Remire, J Duval, C Buffet, J P Etienne, D Dhumeaux, E Dussaix
Affiliations

Serological determination of hepatitis C virus genotype: comparison with a standardized genotyping assay

J M Pawlotsky et al. J Clin Microbiol. 1997 Jul.

Abstract

In patients with chronic hepatitis C, determination of hepatitis C virus (HCV) genotype could be routinely run in the future to tailor treatment schedules. The suitabilities of two versions of a serological, so-called serotyping assay (Murex HCV Serotyping Assay version 1-3 [SA1-3] and Murex HCV Serotyping Assay version 1-6 [SA1-6]; Murex Diagnostics Ltd.), based on the detection of genotype-specific antibodies directed to epitopes encoded by the NS4 region of the genome, for the routine determination of HCV genotypes were studied. The results were compared with those of a molecular biology-based genotyping method (HCV Line Probe Assay [INNO-LiPA HCV]; Innogenetics S.A.), based on hybridization of PCR products onto genotype-specific probes designed in the 5' noncoding region of the genome, obtained with pretreatment serum samples from 88 patients with chronic hepatitis C eligible for interferon therapy. Definitive genotyping was performed by sequence analysis of three regions of the viral genome in all samples with discrepant typing results found among at least two of the three assays studied. In all instances, sequence analysis confirmed the result of the INNO-LiPA HCV test. The sensitivity of SA1-3 was 75% relative to the results obtained by the genotyping assay. The results were concordant with those of genotyping for 92% of the samples typeable by SA1-3. The sensitivity of SA1-6 was 89% relative to the results obtained by the genotyping assay. The results were concordant with those of genotyping for 94% of the samples typeable by SA1-6. Overall, SA1-6 had increased sensitivity relative to SA1-3 but remained less sensitive than the genotyping assay on the basis of PCR amplification of HCV RNA. Cross-reactivities between different HCV genotypes could be responsible for the mistyping of 8 (SA1-3) and 6% (SA1-6) of the samples. Subtyping of 1a and 1b is still not possible with the existing peptides, but discriminating between subtypes may not be necessary for routine use.

PubMed Disclaimer

References

    1. Gastroenterology. 1995 Apr;108(4):1088-96 - PubMed
    1. J Gen Virol. 1993 Nov;74 ( Pt 11):2391-9 - PubMed
    1. J Infect Dis. 1995 Jun;171(6):1607-10 - PubMed
    1. J Clin Microbiol. 1995 May;33(5):1357-9 - PubMed
    1. J Gen Virol. 1995 Oct;76 ( Pt 10):2493-507 - PubMed